Epstein-Barr Virus Reprograms B Cells, Fueling Lupus Progression

A new study has uncovered a strong link between Epstein-Barr virus (EBV) and systemic lupus erythematosus (SLE), a chronic autoimmune disease. Researchers found that EBV reprograms infected B cells, driving the immune system to attack healthy tissues. The findings, published in Science Translational Medicine, suggest the virus plays a central role in SLE progression across multiple organs.

SLE affects around five million people globally, causing damage to the skin, joints, kidneys, heart, and nervous system. While current treatments can slow the disease, no cure exists. The study, led by scientists at Stanford University’s Division of Immunology and Rheumatology, identified how EBV transforms B cells into aggressive 'driver' cells that trigger widespread autoimmunity.

EBV is carried latently by about 95% of the population, but most people do not develop autoimmune disorders. In SLE patients, however, the virus reprograms autoreactive B cells by activating the transcription factor EBNA2. This factor binds to key genes—including CD27, ZEB2, TBX21 (Tbet), and APC—boosting their activity in infected cells.

The altered B cells then act as antigen-presenting drivers, recruiting helper T cells and stimulating a broader immune response. SLE patients were found to have 25 times more EBV-infected B cells than healthy individuals. These infected cells also activate large numbers of antinuclear B cells, worsening tissue damage.

The study suggests this EBV-driven mechanism may not be limited to SLE. Similar processes could contribute to other autoimmune diseases, such as multiple sclerosis, rheumatoid arthritis, and Crohn’s disease.

The research highlights EBV’s role in fueling SLE by hijacking B cells and amplifying immune attacks on healthy tissues. With no cure currently available, these findings could open new avenues for treatments targeting EBV’s interaction with the immune system. Further studies may also explore whether similar mechanisms apply to other autoimmune conditions.